jcm-logo

Journal Browser

Journal Browser

Clinical Updates on Juvenile Idiopathic Arthritis

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology".

Deadline for manuscript submissions: closed (30 June 2024) | Viewed by 2345

Special Issue Editors


E-Mail Website
Guest Editor
Section of Pediatrics, Department of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, Italy
Interests: pediatric rheumatic diseases; juvenile idiopathic arthritis; intra-articular glucocorticoid injections; outcome measures

E-Mail Website
Guest Editor
Section of Pediatrics, Department of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, Italy
Interests: pediatric rheumatic diseases; autoimmunity; juvenile idiopathic arthritis; systemic autoinflammatory diseases

Special Issue Information

Dear Colleagues,

Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disorder and encompasses a group of heterogenous inflammatory joint conditions, each having different clinical signs, symptoms and, in some cases, pathogenetic mechanisms and genetic background. JIA is a leading cause of long-term disability in childhood and it can severely affect the quality of life of patients and their families. Chronic uveitis, one of JIA extra-articular complications, can impair visual function, whereas macrophage activation syndrome, which can complicate the systemic form of JIA, is a life-threatening condition.

In the last decades, impressive improvements in JIA management and long-term outcomes have been made, owing to the constant advances in translational research, the more widespread use of intra-articular glucocorticoids and the availability of a broad spectrum of effective systemic therapies. A treat-to-target approach should be adopted to achieve remission in JIA patients. Valid and reliable outcome measures have been developed and should be used to evaluate disease activity, together with feasible patient/parent-centered assessment tools. The incorporation of imaging techniques, such as ultrasound or magnetic resonance imaging, into the evaluation of children with JIA might enforce the findings of clinical examination and lead to a better definition of the treatment response.

The purpose of this Special Issue is to unravel all these aspects by providing new evidence through original articles and highlighting up-to-date knowledge via literature reviews.

Dr. Roberta Naddei
Prof. Dr. Maria Alessio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • juvenile idiopathic arthritis
  • treatment
  • outcome measures
  • treat-to-target
  • ultrasound
  • biologic agents
  • intra-articular glucocorticoids
  • disease activity

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 264 KiB  
Article
Initial Respiratory System Involvement in Juvenile Idiopathic Arthritis with Systemic Onset Is a Marker of Interstitial Lung Disease: The Results of Retrospective Cohort Study Analysis
by Konstantin E. Belozerov, Eugenia A. Isupova, Natalia M. Solomatina, Ekaterina V. Gaidar, Maria A. Kaneva, Irina A. Chikova, Olga Kalashnikova, Alla A. Kuznetsova, Dmitry O. Ivanov and Mikhail M. Kostik
J. Clin. Med. 2024, 13(13), 3843; https://doi.org/10.3390/jcm13133843 - 29 Jun 2024
Viewed by 2014
Abstract
Background: Pulmonary involvement in systemic juvenile idiopathic arthritis (SJIA) is a rare but dangerous complication. The main risk factors are already known, such as macrophage activation syndrome, a refractory course of systemic juvenile arthritis, infusion reaction to interleukin 1 and/or interleukin 6 blockers, [...] Read more.
Background: Pulmonary involvement in systemic juvenile idiopathic arthritis (SJIA) is a rare but dangerous complication. The main risk factors are already known, such as macrophage activation syndrome, a refractory course of systemic juvenile arthritis, infusion reaction to interleukin 1 and/or interleukin 6 blockers, trisomy 21, and eosinophilia. However, information about respiratory system involvement (RSI) at the onset of SJIA is scarce. Our study aimed to evaluate the specific features of children with SJIA with RSI and their outcomes. Methods: In a single-center retrospective cohort study, we compared the information from the medical records of 200 children with SJIA according to ILAR criteria or SJIA-like disease (probable/possible SJIA) with and without signs of RSI (dyspnea, shortness of breath, pleurisy, acute respiratory distress syndrome, and interstitial lung disease (ILD)) at the disease onset and evaluated their outcomes (remission, development of chronic ILD, clubbing, and pulmonary arterial hypertension). Results: A quarter (25%) of the SJIA patients had signs of the RSI at onset and they more often had rash; hepato- and splenomegaly; heart (pericarditis, myocarditis), central nervous system, and kidney involvement; hemorrhagic syndrome; macrophage activation syndrome (MAS, 44.4% vs. 9.0%, p = 0.0000001); and, rarely, arthritis with fewer active joints, compared to patients without RSI. Five patients (10% from the group having RSI at the onset of SJIA and 2.5% from the whole SJIA cohort) developed fibrosing ILD. All of them had a severe relapsed/chronic course of MAS; 80% of them had a tocilizumab infusion reaction and further switched to canakinumab. Unfortunately, one patient with Down’s syndrome had gone. Conclusion: Patients with any signs of RSI at the onset of the SJIA are required to be closely monitored due to the high risk of the following fibrosing ILD development. They required prompt control of MAS, monitoring eosinophilia, and routine checks of night oxygen saturation for the prevention/early detection of chronic ILD. Full article
(This article belongs to the Special Issue Clinical Updates on Juvenile Idiopathic Arthritis)
Back to TopTop